Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia (Oncotarget. (2017) 8 (49548–49563) DOI: 10.18632/oncotarget.17747

Abstract

Additional information has been added to the Funding section. The complete and updated Funding information is shown below: FUNDING This work has been financially supported by the INCa, the SIRIC Marseille (grant INCa-DGOS-INSERM 6038), the Cancéropôle PACA (grants K_CyTOF 2014 and AML_CyTOF 2016 for J.A.N.), the GS IBiSA and the Agence Nationale de la Recherche (PHENOMIN project for MM HL and EG). The team “Immunity and Cancer” was labeled “Equipe FRM DEQ 201 40329534” (for D.O.). D.O. is a Senior Scholar of the Institut Universitaire de France. All antibodies used were kindly provided by Beckman-Coulter, Marseille, France. Beckman Coulter and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners. A part of this study was funded by a grant from the Wilhelm Sander Stiftung (2015.145.1) to EPvS.